TW200916098A - Agent for lowering uric acid level - Google Patents

Agent for lowering uric acid level Download PDF

Info

Publication number
TW200916098A
TW200916098A TW097122309A TW97122309A TW200916098A TW 200916098 A TW200916098 A TW 200916098A TW 097122309 A TW097122309 A TW 097122309A TW 97122309 A TW97122309 A TW 97122309A TW 200916098 A TW200916098 A TW 200916098A
Authority
TW
Taiwan
Prior art keywords
group
substituted
linear
branched
unsubstituted
Prior art date
Application number
TW097122309A
Other languages
English (en)
Chinese (zh)
Inventor
Satoshi Oda
Kazutaka Shiobara
Yasuhito Yasogi
Kaori Uchino
Nobuko Toyota
Kisaburou Isobe
Tsuyoshi Mizuno
Kumiko Hase
Shin Umeda
Naoki Yajima
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of TW200916098A publication Critical patent/TW200916098A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW097122309A 2007-06-14 2008-06-13 Agent for lowering uric acid level TW200916098A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007157336 2007-06-14
JP2007259870 2007-10-03
JP2007315718 2007-12-06

Publications (1)

Publication Number Publication Date
TW200916098A true TW200916098A (en) 2009-04-16

Family

ID=40129732

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097122309A TW200916098A (en) 2007-06-14 2008-06-13 Agent for lowering uric acid level

Country Status (2)

Country Link
TW (1) TW200916098A (ja)
WO (1) WO2008153129A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107987006A (zh) * 2017-12-20 2018-05-04 华润赛科药业有限责任公司 吲哚类或氮杂吲哚类衍生物、其制备方法和应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5621771B2 (ja) * 2009-06-17 2014-11-12 小野薬品工業株式会社 新規なイミダゾピリジン化合物
CN103649079B (zh) 2010-12-22 2016-11-16 Abbvie公司 丙型肝炎抑制剂及其用途
WO2014151367A1 (en) 2013-03-15 2014-09-25 Janssen Pharmaceutica Nv 1,2,5-substituted benzimidazoles as flap modulators
WO2014151380A1 (en) 2013-03-15 2014-09-25 Janssen Pharmaceutica Nv 1,2,6-substituted benzimidazoles as flap modulators
PL2998296T3 (pl) 2013-05-13 2018-12-31 Shanghai Hengrui Pharmaceutical Co. Ltd. Pochodna kwasu cykloalkilowego, sposób jej otrzymywania i jej zastosowanie farmaceutyczne
CN108084153A (zh) * 2017-12-20 2018-05-29 广东赛烽医药科技有限公司 吡啶基硫代乙酸化合物、组合物及其应用
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
CN110885318B (zh) * 2019-11-28 2022-12-23 苏州大学 苯并恶唑衍生物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2550959C3 (de) * 1975-11-13 1980-12-04 Hoechst Ag, 6000 Frankfurt Tetrazolyl-imidazole und Tetrazolyl--benzimidazole, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
FR2658511B1 (fr) * 1990-02-16 1992-06-19 Union Pharma Scient Appl Nouveaux derives de benzimidazole et d'azabenzimidazole, antagonistes des recepteurs au thromboxane; leurs procedes de preparation, compositions pharmaceutiques les contenant.
US5021448A (en) * 1990-02-22 1991-06-04 Ciba-Geigy Corporation Method of reducing serum uric acid and/or increasing renal uric acid clearance with thromboxane synthetase inhibitor inhibitor and/or thromboxane receptor antagonist
BR9912098A (pt) * 1998-07-15 2001-09-25 Teijin Ltd Derivado de tiobenzimidazol, composição farmacêutica, e, agente preventivo e/ou terapêutico
RU2263674C2 (ru) * 2000-01-17 2005-11-10 Тейдзин Лимитед Бензимидазольное производное, ингибитор человеческой химазы, терапевтический агент и фармацевтическая композиция на его основе
WO2001089519A1 (en) * 2000-05-22 2001-11-29 Nitromed, Inc. Thromboxane inhibitors, compositions and methods of use related applications
UA95788C2 (en) * 2005-12-15 2011-09-12 Ф. Хоффманн-Ля Рош Аг Fused pyrrole derivatives
CA2666658C (en) * 2006-10-06 2015-01-20 Boehringer Ingelheim International Gmbh Chymase inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107987006A (zh) * 2017-12-20 2018-05-04 华润赛科药业有限责任公司 吲哚类或氮杂吲哚类衍生物、其制备方法和应用
CN107987006B (zh) * 2017-12-20 2021-06-01 华润赛科药业有限责任公司 吲哚类或氮杂吲哚类衍生物、其制备方法和应用

Also Published As

Publication number Publication date
WO2008153129A1 (ja) 2008-12-18

Similar Documents

Publication Publication Date Title
TW200916098A (en) Agent for lowering uric acid level
TWI471325B (zh) Indole (Indolizine) derivatives and their pharmaceutical use
JP4926473B2 (ja) 生体内リン輸送を阻害する化合物およびそれを含んでなる医薬
AU2014267974B2 (en) Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof
JP5922116B2 (ja) 複数のプロスタグランジン受容体で作用する全般的な抗炎症反応をもたらす化合物
TW200406412A (en) N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators
WO2017107864A1 (zh) 苯并咪唑类衍生物、其制备方法和应用
NO324049B1 (no) Benzimidazol-derivater, anvendelse av disse for fremstilling av terapeutisk middel for behandling av sykdommer samt farmasoytiske preparater omfattende slike
TW200803852A (en) Inhibitors of histone deacetylase for the treatment of disease
JP4936666B2 (ja) カリウムチャンネル遮断薬としてのスルホンアミド
CN105263915A (zh) 谷氨酰胺酶抑制剂及使用方法
WO2007081978A2 (en) Modulators of hepatocyte growth factor / c-met activity
ES2824801T3 (es) Sal de compuesto heterocíclico sustituido con halógeno
CN104053439A (zh) 1-(5,6-二氯-1h-苯并[d]咪唑-2-基)-1h-吡唑-4-羧酸的葡甲胺盐制剂
BR112020012405A2 (pt) composto cíclico de 6 membros contendo nitrogênio.
WO2017036318A1 (zh) 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用
TWI555744B (zh) Novel EP4 agonists
WO2021249337A1 (zh) 二甲基亚磺酰亚胺衍生物
JP2010522168A (ja) 鉱質コルチコイドレセプターモジュレータ
US20160280640A1 (en) Thromboxane receptor antagonists
US10017521B2 (en) Chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
JP6298172B2 (ja) Ｇｐｒ１４２アゴニスト化合物
US20240025845A1 (en) Metastasis-inhibiting composition of novel methylsulfonamide derivative compound
JP5694959B2 (ja) 三位で置換された３−ベンゾフラニル−インドール−２−オン誘導体、この調製およびこの治療的使用
US20030130325A1 (en) Substituted tryptophan derivatives